Renji Hospital

Researchers

• WDWen Di

Running trials

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Enrolling by invitation

  Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection

  NCT07833046· RenJi Hospital· Source

• Not yet recruiting

  GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease

  NCT07891364· Early phase 1· RenJi Hospital· Source

• Recruiting

  Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

  NCT07575672· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®

  NCT07663526· Phase 4· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Not yet recruiting

  A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

  NCT07632235· Phase 1/2· Shanghai 6th People's Hospital· Source

• Not yet recruiting

  Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer

  NCT07811895· RenJi Hospital· Source

• Recruiting

  Plasma DNA Methylation for Preoperative Classification of Renal Masses

  NCT07874542· RenJi Hospital· Source

• Not yet recruiting

  AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis

  NCT07782294· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

  NCT07521007· Phase 2· Beijing Inno Medicine Co., Ltd.· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer

  NCT07647744· Phase 1· Hrain Biotechnology Co., Ltd.· Source

• Not yet recruiting

  The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching

  NCT07678645· Phase 2· RenJi Hospital· Source

• Recruiting

  A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

  NCT06712654· Phase 2· R1 Therapeutics· Source

• Not yet recruiting

  HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC

  NCT07591805· Phase 2· RenJi Hospital· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

  NCT07283692· Phase 2· RenJi Hospital· Source

• Recruiting

  A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

  NCT07276958· Phase 1· Eli Lilly and Company· Source

• Recruiting

  Biochemical Response and Clinical Outcomes in Patients With PBC

  NCT07449793· RenJi Hospital· Source

• Recruiting

  Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

  NCT07266116· Phase 1/2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Recruiting

  A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis

  NCT07335900· RenJi Hospital· Source

• Recruiting

  A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

  NCT07323173· Phase 1· Nanjing Leads Biolabs Co.,Ltd· Source

• Recruiting

  Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

  NCT07366528· Phase 3· Ruijin Hospital· Source

• Recruiting

  Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

  NCT07265570· Phase 2· InSilico Medicine Hong Kong Limited· Source

• Recruiting

  A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

  NCT07282353· Phase 3· Cascade Pharmaceuticals, Inc· Source

• Recruiting

  Feasibility Study of Diaphragm Synchronized Pacing (DSP) Via the Left Inferior Phrenic Vein (LIPV) Approach

  NCT07392749· RenJi Hospital· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer

  NCT07187635· Tianjin Medical University Second Hospital· Source

• Recruiting

  Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

  NCT07180160· Phase 2· Wenjin Yin· Source

• Not yet recruiting

  A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

  NCT07142200· Phase 2· RenJi Hospital· Source

• Recruiting

  Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer

  NCT07180082· Phase 2· Wenjin Yin· Source

• Recruiting

  Trastuzumab Deruxtecan in Advanced Breast Cancer

  NCT07180264· Wenjin Yin· Source

• Recruiting

  A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

  NCT07066657· Phase 1· ArriVent BioPharma, Inc.· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Takeda· Source

• Not yet recruiting

  A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China

  NCT07026123· RenJi Hospital· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· AbbVie· Source

• Recruiting

  ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

  NCT07327034· Phase 2· Abbisko Therapeutics Co, Ltd· Source

• Recruiting

  A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

  NCT06933472· Phase 3· Alebund Pharmaceuticals· Source

• Recruiting

  A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

  NCT06764615· Phase 2· Takeda· Source

• Not yet recruiting

  Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC

  NCT06916117· Phase 2· RenJi Hospital· Source

• Recruiting

  A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.

  NCT06788431· Early phase 1· ImmuneOnco Biopharmaceuticals (Shanghai) Inc.· Source

• Not yet recruiting

  Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)

  NCT06859931· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis

  NCT06570291· Phase 3· Wuxi Cellular Biopharmaceutical Group Ltd.· Source

• Not yet recruiting

  Early Identification and Treatment of Rare Cardiomyopathy Cohorts

  NCT06794710· RenJi Hospital· Source

• Recruiting

  A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

  NCT07673029· Phase 3· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Source

• Recruiting

  Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer

  NCT07026110· RenJi Hospital· Source

• Recruiting

  Trop2-targeted immunoPET Imaging of Solid Tumors

  NCT06851663· Phase 2/3· RenJi Hospital· Source

• Recruiting

  CD70-targeted immunoPET Imaging of Malignant Cancers

  NCT06852638· Phase 2· RenJi Hospital· Source

Showing 50 of 132.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer10 recruiting
• Pancreatic cancer10 recruiting
• Bladder cancer9 recruiting
• Gastric and oesophageal cancer9 recruiting
• Lupus (SLE)7 recruiting
• Prostate cancer7 recruiting
• Colorectal cancer6 recruiting
• Liver and biliary tract cancer5 recruiting
• Peripheral artery disease5 recruiting
• Cervical cancer4 recruiting
• Coronary artery disease4 recruiting
• Kidney cancer4 recruiting
• Lung cancer4 recruiting
• Primary biliary cholangitis4 recruiting
• Childhood cancers3 recruiting
• Chronic kidney disease3 recruiting
• Crohn's disease3 recruiting
• Dermatomyositis and polymyositis (myositis)3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Alzheimer disease2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Head and neck cancer2 recruiting
• Heart failure2 recruiting
• Multiple myeloma2 recruiting
• Obesity2 recruiting
• Ovarian cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Ulcerative colitis2 recruiting
• Amyloidosis1 recruiting
• Aortic aneurysm1 recruiting
• Aortic stenosis1 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Dilated cardiomyopathy1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• High blood pressure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• IgA nephropathy1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting
• Neuroendocrine tumours1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Osteoarthritis1 recruiting
• Polycystic kidney disease1 recruiting
• Polycystic ovary syndrome1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting
• Thyroid cancer1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Completed

  Construction of Clinical Diagnostic Model for Pulmonary Hypertension

  NCT06979011· RenJi Hospital· Source

• Completed

  A General Anesthesia Regimen for DBS Surgery in Patients With PD

  NCT06658132· RenJi Hospital· Source

• Completed

  Validation of the Reliability and Validity of the New Endoscopic Scoring System for Ulcerative Colitis (CAT-DESIRE Score) and Verification of Its Clinical Practicability

  NCT07608198· Xijing Hospital of Digestive Diseases· Source

• Completed

  A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma

  NCT06656039· RenJi Hospital· Source

• Completed

  Development of AI Model for Renal Tumor Diagnosis Using CT and Lab Tests

  NCT06761742· RenJi Hospital· Source

• Completed

  A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

  NCT06081621· Phase 2· Regend Therapeutics· Source

• Completed

  Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

  NCT05861128· Phase 3· Suzhou Zelgen Biopharmaceuticals Co.,Ltd· Source

• Completed

  Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

  NCT05861102· Phase 3· Suzhou Zelgen Biopharmaceuticals Co.,Ltd· Source

• Completed

  A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

  NCT05770609· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

  NCT07030595· Phase 3· Alebund Pharmaceuticals· Source

• Completed

  A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

  NCT05658484· Phase 4· Biogen· Source

• Completed

  Evaluation of Lung Metastases Based on Ultrashort Echo Time MRI

  NCT05763173· RenJi Hospital· Source

• Completed

  TESTING -ON Post-Trial ObservatioNal Cohort Study

  NCT05434325· The George Institute· Source

• Completed

  A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma

  NCT05620420· RenJi Hospital· Source

• Completed

  Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

  NCT05522231· Phase 2/3· Hutchmed· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  18F-PBR06/Total Body PET Imaging in Patients With STEMI

  NCT05269446· RenJi Hospital· Source

• Completed

  Comparison Between Upgraded '2C3L' vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation

  NCT04497376· Beijing Anzhen Hospital· Source

• Completed

  A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

  NCT04956432· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source

• Completed

  Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

  NCT04672330· Phase 2· RenJi Hospital· Source

• Completed

  A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  NCT04172675· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

  NCT04108208· Phase 4· Janssen Research & Development, LLC· Source

• Completed

  Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

  NCT03748953· Phase 3· Millennium Pharmaceuticals, Inc.· Source

• Completed

  A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

  NCT03217812· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

  NCT03062358· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Transanal Versus Laparoscopic Total Mesorectal Excision For Rectal Cancer

  NCT02966483· Sun Yat-sen University· Source

• Completed

  AccuIMR Predicts Microvascular Obstruction and Infarct Size in STEMI Patients

  NCT06947564· RenJi Hospital· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer110 works · 9 trials
• Colorectal cancer82 works · 7 trials
• Prostate cancer62 works · 9 trials
• Gastric and oesophageal cancer46 works · 11 trials
• Pancreatic cancer44 works · 10 trials
• Ovarian cancer30 works · 2 trials
• Kidney cancer29 works · 9 trials
• Bladder cancer29 works · 12 trials
• Lupus (SLE)29 works · 9 trials
• Polycystic ovary syndrome16 works · 1 trial
• Brain aneurysm15 works · 0 trials
• Dermatomyositis and polymyositis (myositis)14 works · 5 trials
• Systemic sclerosis (scleroderma)12 works · 4 trials
• Thyroid cancer11 works · 1 trial
• Myasthenia gravis7 works · 1 trial
• Primary biliary cholangitis6 works · 4 trials
• Liver cirrhosis6 works · 1 trial
• ANCA-associated vasculitis4 works · 0 trials
• IgA nephropathy4 works · 4 trials